Statement: In the primary trial 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients had Unexpected adverse events.
Primary_evidence: Outcome Measurement:    Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)   Percentage of patients with AEs.   Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient. Results 1:    Arm/Group Title: Single Arm   Arm/Group Description: fulvestrant (Faslodex  )   Overall Number of Participants Analyzed: 81   Measure Type: Number   Unit of Measure: Percentage of participants  Adverse Events(AE): 81.5        (71.3 to 89.3)   ADR; based on current South Korea label.: 38.3        (27.7 to 49.7)   Serious AE: 11.1        (5.2 to 20.1)   Serious ADR: 0        (0 to 4.4)   Unexpected AE: 71.6        (60.5 to 81.1)   Unexpected ADR: 24.7        (15.8 to 35.5)